Rising Beef Costs Impact McDonald's Stock Performance
Money

Rising Beef Costs Impact McDonald's Stock Performance

authorBy Dave Ramsey
DateJul 28, 2026
Read Time3 min
This report analyzes the recent performance of McDonald's Corporation (MCD) during the second quarter of 2026, highlighting the impact of rising beef prices on its stock and investor perception. It references insights from Carillon Tower Advisers' investor letter, which also discusses broader market trends, including the surge in AI-related stocks and the economic landscape.

Navigating Market Headwinds: McDonald's Responds to Economic Shifts

Overview of Q2 2026 Market Dynamics and Carillon Eagle Growth & Income Fund's Perspective

The second quarter of 2026 witnessed a significant rally in AI-related equities, primarily benefiting highly cyclical semiconductor and optical companies. The S&P 500 index saw a 15.2% increase, while the semiconductor sector surged by 87.8%. Unlike previous AI-driven booms dominated by mega-cap firms, this period saw substantial growth in smaller technology companies. However, software and service stocks faced declines as the potential disruptive impact of AI raised investor questions. Geopolitical tensions, such as the Iran conflict, led to a temporary rise in oil prices, contributing to inflation and interest rate concerns. Despite this volatility, economic fundamentals and corporate earnings remained robust. Projections indicated a 25% increase in S&P 500 earnings for 2026 and a 15% rise for 2027, with the market trading at approximately 20 times earnings. The Carillon Eagle Growth & Income Fund maintains its investment strategy, focusing on financially robust companies with sustainable earnings growth capable of performing well across diverse economic conditions.

McDonald's Corporation's Performance Amidst Rising Beef Costs

In its Q2 2026 investor letter, the Carillon Eagle Growth & Income Fund specifically addressed McDonald's Corporation (NYSE: MCD). The fast-food giant's stock experienced a decline in investor confidence, largely attributed to an increase in beef prices. This surge in beef costs was partly driven by concerns surrounding the New World screwworm parasite. As of July 27, 2026, McDonald's stock closed at $270.67 per share, reflecting a 0.13% return over the previous month and a 10.57% loss over the past 52 weeks. The company's market capitalization stood at $192.31 billion, with its 52-week trading range between $260.96 and $341.75. Despite facing more challenging year-over-year comparisons in the upcoming quarter, McDonald's has implemented value-driven initiatives that have successfully attracted some price-sensitive consumers, even as this customer segment continues to face economic pressures.

Investment Landscape and Future Outlook for McDonald's

Despite its challenges, McDonald's Corporation (NYSE: MCD) was held by 83 hedge fund portfolios at the end of the first quarter, a slight decrease from 91 in the preceding quarter. While acknowledging McDonald's investment potential, some analysts suggest that certain AI stocks might offer greater upside and lower downside risk. The broader investment community continues to seek out undervalued AI opportunities, especially those that could benefit from evolving trade policies and domestic manufacturing trends. Investors are encouraged to explore various investment reports to identify top picks and understand market movements across different sectors.

More Articles
Money
Trucking Market Evolution: Why Capacity Remains Constrained
Aaron Graft, CEO of Triumph Financial, explains that the current trucking market upcycle is structurally different from previous ones, primarily due to increased litigation, regulation, and legislation. These factors create significant barriers to entry, preventing the rapid surge of new capacity typically seen during market upturns. This fundamental shift suggests that the current tight market conditions could persist for an extended period, impacting both profitability and the availability of drivers in the industry.
By Natalie PaceJul 28, 2026
Money
AMD's AI-Driven Server CPU Renaissance Boosts Market Performance
Advanced Micro Devices (AMD) experienced a significant surge in market value, driven by a renaissance in server CPUs powered by agentic AI. Despite not being held by the Columbia Seligman Global Technology Fund in Q2 2026, the company's shares gained 178.94% over 52 weeks, closing at $494.95. This growth highlights the increasing demand for AI infrastructure, semiconductors, and related technologies, reflecting broader positive trends in the tech sector despite geopolitical uncertainties and rising interest rates.
By Natalie PaceJul 28, 2026
Money
Core Scientific Forges AI Data Center Alliance with AMD
Core Scientific has announced a significant collaboration with chipmaker Advanced Micro Devices (AMD) to establish a new artificial intelligence data center. This partnership involves AMD leasing 529 megawatts of AI capacity from Core Scientific for 15 years, a deal projected to generate over $14 billion in revenue for Core Scientific. This strategic move highlights Core Scientific's transition from Bitcoin mining to becoming a key player in the AI infrastructure sector, with operations set to commence in 2027.
By Ramit SethiJul 28, 2026
Money
Cryptocurrency Markets Face Downturn Ahead of Federal Reserve Meeting
Bitcoin and Ethereum experienced significant price drops on Tuesday, July 28, 2026, as investors braced for the Federal Reserve's two-day meeting. Bitcoin opened 2.5% lower at $63,706.66, further declining to $63,327.39. Ethereum also fell 3.2% to $1,890.67, reaching $1,877.71. Market volatility is high due to potential interest rate hikes and global geopolitical developments, making the Fed's decision particularly impactful.
By Chika UwazieJul 28, 2026
Money
AstraZeneca's Pharmaceutical Pipeline: A Tale of Divergent Analyst Views
AstraZeneca's drug development pipeline is drawing contrasting opinions from financial analysts. Citibank has raised its price target for the company, citing solid second-quarter performance and a robust pipeline with numerous Phase III trials expected in 2027. Conversely, Deutsche Bank maintains a 'sell' rating, expressing a more cautious outlook. Despite a recent trial setback, AstraZeneca's CEO remains confident in achieving the company's ambitious revenue targets, backed by strong growth in oncology and rare disease sectors.
By Dave RamseyJul 28, 2026